The content on this site is intended for healthcare professionals only
Dr Harshad Kulkarni talks to ecancer at the 2013 NCRI Cancer Conference in Liverpool about PET/CT on neuroendocrine tumours.
A German multi-institutional registry study found that this is an effective therapy for patients with G1-2 neuroendocrine tumours with a survival advantage of several years compared to other therapies and only minor side effects.
The concept of theranostics has now been translated to other malignancies such as prostate cancer.
Rationale for routine use of IORT for early breast cancer and data for specific indications
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )](https://cdn.ecancer.org/44737-m.jpg)
Rationale for routine use of IORT for early breast cancer and data for specific indications
Single-dose IORT during lumpectomy for breast cancer an innovative patient-centred treatment
Global adoption of single-shot targeted IORT for breast cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
